ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptive Biotechnologies Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$23.95−0.07 (-0.29%)
Close on Oct 19, 2026
- Market cap
- $3.83B
- P/E (TTM)
- –
- Dividend yield
- –
Adaptive Biotechnologies Corp revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRD | $66.17M | $67.09M | $61.89M | $56.79M | $49.94M | $43.72M | $40.15M | $37.47M | $35.28M | $32.63M | $30.76M | $24.67M | 92.5% | +32.5% |
| Immune Medicine | $5.39M | $3.78M | $9.79M | $37.19M | $8.94M | $8.72M | $7.31M | $8.97M | $7.91M | $9.25M | $15.02M | $13.25M | 7.5% | -39.8% |
By product or service
By region
From the segment and revenue-disaggregation notes of Adaptive Biotechnologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.